TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02044380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40, 30, or 20mg tablets taken once daily, dosage depending on tolerability
Study: NCT04361461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate + Azythromycin
Description: 400 mg, orally, every 12 hours x 2 doses (loading dose) and then 400 mg, once a day, orally, for 10 days associated with azithromycin, intravenously or orally, 500 mg / day, for 1 day and then 250mg / day for another 4 days.
Study: NCT02501096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
Study: NCT04659785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Take Fluzoparib orally（either at 50,100mg bid）until disease progression or appearance of unbearable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Take apatinib orally (either at 375mg、500mg、750mg qd）until disease progression or appearance of unbearable toxicity
Study: NCT01416168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McCorkle Model Intervention
Description: The intervention will consist each week in a home visit and a phone call. The GNP conducting the home visit will identify current problems using a comprehensive geriatric assessment (CGA) and record problems on the Intervention and Recommendation Data Sheet. In addition, the cases will be reviewed at a weekly Intervention Team meeting between the intervention GNP (VM, CV), the geriatrician (VP), and the intervention PI (JO). That team meeting will also record how intervention goals for the various problems are met, using the instruments and criteria developed during our pilot study5. To ensure optimal consistency and an up-to-date evidence-based approach over the 4 years of the intervention, treatment recommendations will be offered according to national evidence-based treatment guidelines.
Study: NCT03200782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
Study: NCT01129375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration:oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration:oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: omeprazole
Description: Pharmaceutical form: delayed-release capsule~Route of administration:oral
Study: NCT03044834

Intervention type: OTHER
Intervention: PPB
Description: Global current care
Study: NCT03368300

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and biological exam
Description: The study will include a clinical, neuropsychological, oculomotor, food intake and environmental exposure assessment. Blood samples will be taken to constitute a library of plasma, DNA and serum. The harvesting of samples will be part of a subsequent study. Consent for possible post-mortem neuropathological analysis will be proposed.~All the patients accepting it will be followed by a 5-year longitudinal follow-up. The longitudinal follow-up bi-annual and then annual will include a clinical evaluation, a questionnaire of dependence and a questionnaire of monitoring of exposure to certain environmental factors~All controls must answer a questionnaire of environmental exposure factors, oculomotor test, and blood sample (3 collections: DNA, serum, plasma).
Study: NCT04067050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A asphere
Description: Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Habitual spectacles
Study: NCT01983267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cannabis
Description: use of cannabis oil or cigarets
Study: NCT02691234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy and debridement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: debridement and cleaning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: debridement and cleaning
Study: NCT01133730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active treatment
Description: US-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: US-guided TFP block with 20ml of 5% dextrose solution
Study: NCT00967330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 10mg/kg iv every 2 weeks
Study: NCT03200782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
Study: NCT03173404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: The hysteroscopy is the visualization of the cervical canal and uterine cavity with a camera. Patients randomized to group I underwent hysteroscopy prior to the IVF cycle.
Study: NCT02468726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NER1008 enema
Description: NER1008 enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fleet
Description: Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
Study: NCT02254200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatmax group
Description: For the Fatmax group each session will consist of 40-50 min of continuous exercise with an intensity that corresponded to the individual Fatmax (moderate intensity)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT group
Description: For HIIT group, each session will consist of 10x60-s cycling intervals interspersed with 60-s of recovery. The workloads will be selected to elicit a heart rate of \~90% maximal heart rate during the intervals with a pedal rate of 90-100 revolutions.min-1, whereas during recovery, the participants will be allowed to pedal against a resistance of 50 W
Study: NCT01177644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDS 1.0
Study: NCT03115619

Intervention type: DRUG
Intervention: Pirfenidone
Description: Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC).
Study: NCT02400372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medihoney dressing
Description: to evaluate the effect of medihoney dressing on the healing of split thickness skin graft donor site
Study: NCT02353715

Intervention type: DRUG
Intervention: Enzalutamide

Intervention type: DRUG
Intervention: Abiraterone acetate
Study: NCT03994185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of WRAPSODY stent graft
Description: Placement of WRAPSODY stent graft into the iliac arteries and/or aortic bifurcation.
Study: NCT02353715

Intervention type: DRUG
Intervention: Sipuleucel-T
Study: NCT02935530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: s-LMWH
Description: 2125KU, subcutaneous injection of 5-10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH
Description: 4250KU, subcutaneous injection of 5-10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: 20mg, injection for 5-10 days
Study: NCT03958357

Intervention type: DEVICE
Intervention: Advanced Gynecological Applicator configuration
Description: The Advanced Gynecological Applicator Venezia configuration is a gynaecological applicator for intracavitary and interstitial brachytherapy. The applicator consists of tubes, caps and templates to place needles, which can be combined to reach a wide range of target areas. The tubes and possibly used needles, guide the radioactive source of the afterloader to the target volume. Dose optimization and dose fractionation is performed with the goal of adapting the dose to the target volume without exceeding the dose volume constraints for the surrounding normal tissues according to the standard cervical cancer treatment of the centre.
Study: NCT02859103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine
Description: Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
Study: NCT01593124

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nonoxynol-9
Description: Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
Study: NCT03599791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT
Description: Dymista Nasal spray suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine Hydrochloride 0.137 MG/ACTUAT
Description: AZEP Nasal spray solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate 0.05 MG/ACTUAT
Description: Fluticasone propionate nasal spray suspension
Study: NCT01469273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mutaflor® Suspension
Description: Application of Mutaflor-Suspension on 10 consecutive days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mutaflor® Suspension
Description: Application of Mutaflor-Suspension on 10 consecutive days.
Study: NCT04684069

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-axis syringe free in-plane
Description: Long-axis syringe-free in-plane catheter placement
Study: NCT00967330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 125mg/m2 iv every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: 75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
Study: NCT04347720

Intervention type: DRUG
Intervention: Indomethacin
Description: Intravenous formulation

Intervention type: DRUG
Intervention: Ibuprofen
Description: Intravenous and oral formulations

Intervention type: DRUG
Intervention: Ibuprofen
Description: Intravenous and oral formulations
Study: NCT04684069

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Short-axis out-of-plane
Description: Short-axis out-of-plane catheter placement
Study: NCT02003534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.15% Brimonidine Tartrate
Description: 0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
Study: NCT03920254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 Dose A
Description: See Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 Dose B
Description: See Arm description
Study: NCT03200782

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral placebo (winthrop tablet)
Description: subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo (winthrop tablet)
Description: subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous placebo (0.67 ml of 0.9% sodium chloride)
Description: subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: subcutaneous placebo (0.67 ml of 0.9% sodium chloride)
Description: subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
Study: NCT01885390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROX COUPLER
Description: The COUPLER will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
Study: NCT03920254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 Dose C
Description: See Arm description
Study: NCT03263624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide laser
Description: One hand of each patient will receive three sessions of fractional carbon dioxide laser at four- week interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Cream 0.1%
Description: tazarotene cream 0.1% once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene Cream 0.1%
Description: tazarotene cream 0.1% once daily
Study: NCT01952236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web+Mobile
Description: We propose to evaluate the efficacy and acceptability of a Web+Mobile tobacco cessation intervention in a 2-arm Randomized Controlled Trial with 1,271 adult study participants who agree to quit smoking within a pre-specified amount of time. Participants who meet eligibility criteria will be randomly assigned to either (a) an enhanced Web Only intervention or (b) an enhanced Web+Mobile intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web Only
Description: A Web-based PC-delivered best practices smoking cessation intervention.
Study: NCT02056795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Asia-Med Special No 16 (0.30x30mm) needles
Description: Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Streitberger placebo needles (Asia-Med, 0.03 x 30 mm)
Description: As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
Study: NCT02820454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGuIX
Description: A single intravenous injection on day 1. Dose level 1: 15mg/kg; Dose level 2: 30mg/kg, Dose level 3: 50mg/kg; Dose level 4: 75mg/kg; Dose level 5: 100mg/kg
Study: NCT01037946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral sessions
Description: Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
Study: NCT00571129

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DCR with no tubes or mitomycin
Description: The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.~In revision group patients were randomized into the two groups,ether with or without application of mitomycin C after DCR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DCR with no tubes or mitomycin
Description: The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.~In revision group patients were randomized into the two groups,ether with or without application of mitomycin C after DCR
Study: NCT02820454

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole brain radiation therapy
Description: 30Gy in 10 sessions of 3Gy (5 days a week in weeks 1-2); first session 4 hours after AGuIX injection.
Study: NCT03709004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacifier
Description: Pacifier given to mom.
Study: NCT00554450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, once daily
Study: NCT02340065

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard colonoscopy
Description: examination of the colon with a conventional colonoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff-assisted colonoscopy
Description: examination of the colon with Endocuff-assisted colonoscopy
Study: NCT02223338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Use of topical ciprofloxacin 4x daily for 3 days after intravitreal injection using standard aseptic techniques with Povidone-Iodine is a common practice intervention in the United States, and is thought by some to reduce the risk of post-injection endophthalmitis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Aseptic Technique
Description: Patients in this group will have received Povidone-Iodine Only following injections of anti-VEGF agents at least 3 times in the last 6 months.
Study: NCT02525588

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon CS fixed bearing total knee prosthesis
Description: The patient will receive either the N2Vac polyethylene inlay or the X3 polyethylene inlay for their CS total knee.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon CS fixed bearing total knee prosthesis
Description: The patient will receive either the N2Vac polyethylene inlay or the X3 polyethylene inlay for their CS total knee.
Study: NCT03691597

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: improved patient satisfaction ,marginal integrity, shade match and gingival health
Description: For both groups N.Awill make a recall visit after6 months and after 12 months:~1. Patient satisfaction will be performed according to questionnaire after One year.Questionnaire will contain several questions that evaluate patient satisfaction.~2. The color will be measured using spectrophotometer Vita easy shade in the same delivery visit ,after 6months and after one year .~3. Images will be captured using digital handheld light microscope (Celestron 5 Megapixel Resolution, USA) that is fixed on a film holder on a specific distance for the standardization of all the images will be captured by the microscope for all the patients.(22)~4. Images will be analyzed using imageJ software to measure marginal gap.~5. Gingival health will be measured using G

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: improved patient satisfaction ,marginal integrity, shade match and gingival health
Description: For both groups N.Awill make a recall visit after6 months and after 12 months:~1. Patient satisfaction will be performed according to questionnaire after One year.Questionnaire will contain several questions that evaluate patient satisfaction.~2. The color will be measured using spectrophotometer Vita easy shade in the same delivery visit ,after 6months and after one year .~3. Images will be captured using digital handheld light microscope (Celestron 5 Megapixel Resolution, USA) that is fixed on a film holder on a specific distance for the standardization of all the images will be captured by the microscope for all the patients.(22)~4. Images will be analyzed using imageJ software to measure marginal gap.~5. Gingival health will be measured using G
Study: NCT04870502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Controlled ovarian stimulation by Combined Clomiphene Citrate and Ubiquinol Versus hMG
Description: In group A, controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals). In group B, Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response. Patients were instructed not to take any non-study drugs during the whole study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Controlled ovarian stimulation by Combined Clomiphene Citrate and Ubiquinol Versus hMG
Description: In group A, controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals). In group B, Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response. Patients were instructed not to take any non-study drugs during the whole study period.